Compared with healthy controls, interleukin-6 was significantly higher (<i>p</i> = 0.0001) in patients with primary open-angle glaucoma and interleukin-1β (<i>p</i> = 0.0144), interleukin-6 (<i>p</i> < 0.0001), and interleukin-10 (<i>p</i> = 0.0392) were higher in patients with dry eye disease.
This study indicates that the three CsA formulations effectively modulated TLR4, TGFβ1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.
On the contrary, the mRNA levels of interleukin (IL)-1β, -6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were increased in the DE corneas of the control mice and were reduced by all treatments; in particular, IL-6 was significantly suppressed.